3/19
09:00 am
gral
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Medium
Report
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
3/18
09:00 am
gral
LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED
Low
Report
LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED
3/18
08:22 am
gral
GRAIL (GRAL) was upgraded by TD Cowen from "hold" to "buy". They now have a $65.00 price target on the stock.
Low
Report
GRAIL (GRAL) was upgraded by TD Cowen from "hold" to "buy". They now have a $65.00 price target on the stock.
3/12
04:44 pm
gral
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor [Yahoo! Finance]
Low
Report
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor [Yahoo! Finance]
3/12
04:30 pm
gral
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
Low
Report
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
3/12
09:00 am
gral
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Low
Report
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
3/4
02:15 pm
gral
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Low
Report
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
3/2
04:01 pm
gral
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/1
10:05 am
gral
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment [Yahoo! Finance]
Low
Report
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment [Yahoo! Finance]
2/24
04:02 pm
gral
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
Medium
Report
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
2/24
09:02 am
gral
GRAIL (NASDAQ:GRAL) was given a new $60.00 price target on by analysts at Morgan Stanley.
High
Report
GRAIL (NASDAQ:GRAL) was given a new $60.00 price target on by analysts at Morgan Stanley.
2/24
08:10 am
gral
GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm
High
Report
GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm
2/20
02:45 pm
gral
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
Low
Report
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
2/20
09:13 am
gral
GRAIL (NASDAQ:GRAL) was given a new $82.00 price target on by analysts at Robert W. Baird.
Low
Report
GRAIL (NASDAQ:GRAL) was given a new $82.00 price target on by analysts at Robert W. Baird.
2/20
08:02 am
gral
GRAIL (NASDAQ:GRAL) was given a new $80.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
GRAIL (NASDAQ:GRAL) was given a new $80.00 price target on by analysts at Canaccord Genuity Group Inc..
2/20
12:16 am
gral
GRAIL Inc (GRAL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Challenges [Yahoo! Finance]
Medium
Report
GRAIL Inc (GRAL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Challenges [Yahoo! Finance]
2/19
09:27 pm
gral
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Medium
Report
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
2/19
04:02 pm
gral
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
High
Report
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
2/19
04:01 pm
gral
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
High
Report
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
2/19
07:07 am
gral
GRAIL (NASDAQ:GRAL) is now covered by analysts at TD Cowen. They set a "hold" rating on the stock.
Low
Report
GRAIL (NASDAQ:GRAL) is now covered by analysts at TD Cowen. They set a "hold" rating on the stock.
2/18
06:57 am
gral
GRAIL (NASDAQ:GRAL) was upgraded by analysts at Robert W. Baird to a "strong-buy" rating.
Low
Report
GRAIL (NASDAQ:GRAL) was upgraded by analysts at Robert W. Baird to a "strong-buy" rating.
2/17
07:17 am
gral
GRAIL (NASDAQ:GRAL) was given a new $113.00 price target on by analysts at Robert W. Baird.
Low
Report
GRAIL (NASDAQ:GRAL) was given a new $113.00 price target on by analysts at Robert W. Baird.
2/16
09:00 am
gral
GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
Low
Report
GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
1/29
07:25 pm
gral
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
Medium
Report
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
1/26
10:02 am
gral
GRAIL (NASDAQ:GRAL) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
GRAIL (NASDAQ:GRAL) had its "buy" rating reaffirmed by analysts at Guggenheim.